Transcenta and EirGenix Collaborate to Advance Integrated Continuous Biomanufacturing Technologies

Shots: EirGenix has entered into a strategic collaboration and non-exclusive licensing agreement with Transcenta for its Highly Intensified Continuous Bioprocessing (HiCB) platform Under the agreement, Transcenta will grant EirGenix a non-exclusive license to its HiCB platform, incl. continuous perfusion & integrated hybrid continuous purification process technologies, as well as documentation, know-how & regulatory support to…

ByRidhi RastogiDecember 29, 2025

NEWS

ABL Bio Secures Upfront Payment and Equity Investment from Lilly to Accelerate Grabody Programs

Shots: ABL Bio has secured a total of $55M, incl. $40M upfront & $15M in equity investment, from Eli Lilly under their ~$2.602B license, research & collaboration agreement Under the deal, ABL Bio & Eli Lilly are jointly advancing multiple therapeutic candidates across diverse modalities, leveraging ABL Bio’s Grabody platform for collaborative research & development…

ByRidhi RastogiDecember 29, 2025

NEWS

Italfarmaco and JCR Pharmaceuticals Partner to Commercialize Givinostat in Japan

Shots: Italfarmaco has entered into an exclusive licensing agreement with JCR Pharmaceuticals for the development and commercialisation of givinostat in Japan As per the deal, JCR will secure exclusive rights to commercialize givinostat, marketed as Duvyzat in US, EU & UK, for Duchenne muscular dystrophy (DMD) in Japan & will lead local execution of clinical…

ByRidhi RastogiDecember 26, 2025

NEWS

Rectify Pharmaceuticals and Boehringer Ingelheim Partner to Develop Small Molecules for Chronic Kidney Disease (CKD)

Shots: Rectify has entered into a strategic research & licensing agreement with BI to accelerate the development of small molecule therapies for CKD & other conditions Collaboration will leverage Rectify’s positive functional modulators (PFM) platform to develop oral small molecules that restore or enhance ABCC6 function, targeting pathologic calcification to slow disease progression in CKD, Pseudoxanthoma elasticum,…

ByRidhi RastogiDecember 24, 2025

NEWS

Ipsen Signs ~$1.06B Deal with Simcere Zaiming for SIM0613

Shots: Ipsen has entered into an exclusive licensing agreement with Simcere Zaiming for SIM0613 to treat solid tumors with the highest unmet needs Ipsen will secure global rights to SIM0613 outside Greater China, gain manufacturing rights after technology transfer, & assume responsibility for all development activities beyond Greater China, incl. P-I preparation & IND/CTA submissions As…

ByRidhi RastogiDecember 24, 2025

NEWS

Windward Bio Secures Exclusive Rights to WIN027 from Qyuns Therapeutics in a ~$700M Deal

Shots: Windward Bio via its affiliate, LE2025 Therapeutics, has entered into a licensing agreement with Qyuns to develop & commercialize WIN027 (QX027N; anti-TSLPxIL-13 bsAb) As per the deal, Windward will obtain exclusive rights to develop, manufacture, & commercialize WIN027 outside of China, with Qyuns receiving an upfront payment, equity, & development, regulatory, & commercial milestones,…

ByRidhi RastogiDecember 24, 2025

NEWS

Jacobio Pharma Forge ~$2B+ Partnership with AstraZeneca for JAB-23E73

Shots: Jacobio Pharma entered a global exclusive licensing agreement with AstraZeneca for JAB-23E73, granting AstraZeneca exclusive development & commercialization rights outside China, while both companies will jointly develop & commercialize in China As per the deal, Jacobio will receive $100M upfront, and is eligible up to $1.91B in development & commercial milestones, and tiered royalties…

ByRidhi RastogiDecember 22, 2025

NEWS

GeneScience Pharmaceutical Inks ~$1.3B Deal with Yarrow Bioscience for GS-098

Shots: GeneScience has entered into an exclusive global ex-China license agreement with Yarrow, backed by RTW Investments, for GS-098 (YB-101 outside of China) to treat Graves’ disease (GD) & thyroid eye disease (TED) As per the deal, Yarrow will obtain exclusive global ex-China rights to develop, manufacture, & commercialize GS-098 for GD & TED,…

ByRidhi RastogiDecember 17, 2025

NEWS

Harbour BioMed and BMS Collaborate in ~$1.1B Deal to Advance Next-Generation Multi-Specific Antibodies

Shots: Harbour BioMed has entered into a multi-year, global strategic collaboration & license agreement with BMS to discover & develop next-generation multi-specific antibodies leveraging the Harbour Mice platform As per the deal, Harbour BioMed & BMS will jointly identify & advance multi-specific antibody programs, with Harbour eligible for $90M in total payments, ~$1.03B in development & commercial…

ByRidhi RastogiDecember 17, 2025

NEWS

ADEL and Sanofi Ink ~$1.04B Global Licensing Deal for ADEL-Y01

Shots: ADEL has entered into an exclusive worldwide license agreement with Sanofi for the development & commercialization of ADEL-Y01 & related backup compounds As per the deal, ADEL will receive a non-refundable payment of $80M upfront plus development & commercial milestones, representing the total deal value of ~$1.04B, tiered royalties on net sales ranging up…

ByRidhi RastogiDecember 16, 2025

Transcenta and EirGenix Collaborate to Advance Integrated Continuous Biomanufacturing Technologies

ABL Bio Secures Upfront Payment and Equity Investment from Lilly to Accelerate Grabody Programs

Italfarmaco and JCR Pharmaceuticals Partner to Commercialize Givinostat in Japan

Rectify Pharmaceuticals and Boehringer Ingelheim Partner to Develop Small Molecules for Chronic Kidney Disease (CKD)

Ipsen Signs ~$1.06B Deal with Simcere Zaiming for SIM0613

Windward Bio Secures Exclusive Rights to WIN027 from Qyuns Therapeutics in a ~$700M Deal

Jacobio Pharma Forge ~$2B+ Partnership with AstraZeneca for JAB-23E73

GeneScience Pharmaceutical Inks ~$1.3B Deal with Yarrow Bioscience for GS-098

Harbour BioMed and BMS Collaborate in ~$1.1B Deal to Advance Next-Generation Multi-Specific Antibodies

ADEL and Sanofi Ink ~$1.04B Global Licensing Deal for ADEL-Y01

Contact US

FOLLOW US